Torcetrapib increases mortality in patients with a high risk of cardiovascular disorders;Torcetrapib verhoogt sterfte bij patiënten met een toegenomen risico op cardiovasculaire aandoeningen

Nederlands Tijdschrift voor Geneeskunde

Volumn 152, Issue 19, 2008, Pages 1088-1090

  Rensen, P C N ^a   Jukema, J W ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; ELECTROLYTE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TORCETRAPIB;

ALDOSTERONE BLOOD LEVEL; ATHEROSCLEROSIS; BICARBONATE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG FATALITY; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; MORTALITY; NOTE; SIDE EFFECT; SODIUM BLOOD LEVEL;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; HUMANS; HYPERCHOLESTEROLEMIA; PATIENT SELECTION; QUINOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; WATER-ELECTROLYTE BALANCE;

EID: 44949256365     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (12)

1. Gordon DJ, Rifkind BM. High-density lipoprotein - the clinical implications of recent studies. N Engl J Med. 1989;321:1311-6.
2. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004;350:1505-15.
3. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. ILLUMINATE Investigators. N Engl J Med. 2007;357:2109-22.
4. Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. ILLUSTRATE Investigators. N Engl J Med. 2007;356:1304-16.
5. Kastelein JJ, Leuven SI van, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. RADIANCE 1 Investigators. N Engl J Med. 2007;356:1620-30.
6. Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. RADIANCE 2 Investigators. Lancet. 2007;370:153-60.
7. Suzuki J, Iwai M, Mogi M, Oshita A, Yoshii T, Higaki J, et al. Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. Arterioscler Thromb Vasc Biol. 2006;26:917-21.
8. Boekholdt SM, Kuivenhoven JA, Wareham NJ, Peters RJ, Jukema JW, Luben R, et al. Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European prospective investigation into cancer and nutrition)-Norfolk population study. Circulation. 2004;110:1418-23.
9. Schwartz CC, VandenBroek JM, Cooper PS. Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans. J Lipid Res. 2004;45:1594-607.
10. Haan W de, Hoogt CC van der, Westerterp M, Hoekstra M, Dallinga-Thie GM, Princen HM, et al. Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.-CETP mice. Atherosclerosis. 2008;197:57-63.
11. Haan W de, Vries-van der Weij J de, Hoorn JWA van der, Gautier T, Hoogt CC van der, Westerterp M, et al. Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more inflammatory lesions than atorvastatin. Circulation. [ter perse].
12. Krishna R, Anderson MS, Bergman AJ, Jin B, Fallon M, Cote J, et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet. 2007;370:1907-14.